Anti-CTLA-4 based therapy elicits humoral immunity to galectin-3 in patients with metastatic melanoma

The combination of CTLA-4 blockade ipilimumab (Ipi) with VEGF-A blocking antibody bevacizumab (Bev) has demonstrated favorable clinical outcomes in patients with advanced melanoma. Galectin-3 (Gal-3) plays a prominent role in tumor growth, metastasis, angiogenesis, and immune evasion. Here we report...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Xinqi, Giobbie-Hurder, Anita, Connolly, Erin M., Li, Jingjing, Liao, Xiaoyun, Severgnini, Mariano, Zhou, Jun, Rodig, Scott, Hodi, F. Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5993498/
https://www.ncbi.nlm.nih.gov/pubmed/29900046
http://dx.doi.org/10.1080/2162402X.2018.1440930

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5993498/
https://www.ncbi.nlm.nih.gov/pubmed/29900046
http://dx.doi.org/10.1080/2162402X.2018.1440930

Ejemplares similares